ADRIATIC: When face value is enough

Alfredo Addeo; Stephen V Liu

doi:10.1016/j.medj.2024.10.004

ADRIATIC: When face value is enough

Med. 2024 Nov 8;5(11):1348-1350. doi: 10.1016/j.medj.2024.10.004.

Authors

Alfredo Addeo¹, Stephen V Liu²

Affiliations

¹ Oncology Service, University Hospital Geneva, Geneva, Switzerland. Electronic address: [email protected].
² Georgetown University, Washington, DC, USA.

PMID: 39520980
DOI: 10.1016/j.medj.2024.10.004

Abstract

The ADRIATIC¹ study marks a major advancement in limited-stage small cell lung cancer (LS-SCLC), showing that consolidation therapy with durvalumab after chemoradiation significantly improves overall survival (OS) and progression-free survival (PFS). This establishes durvalumab as the new standard of care for LS-SCLC.

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Chemoradiotherapy / methods
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Lung Neoplasms* / therapy
Progression-Free Survival
Small Cell Lung Carcinoma* / pathology
Small Cell Lung Carcinoma* / therapy

Substances

Antibodies, Monoclonal
durvalumab
Antineoplastic Agents, Immunological